Login to Your Account

Shares of Immunovaccine Inc. (TSX:V:IMV) gained 14.4 percent Monday, to close at C$1.11 (US$1.01), after the Halifax, Nova Scotia-based company reported that monkeys dosed with an Ebola vaccine employing its Depovax formulation technology survived exposure to a lethal dose of the virus in a challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID).
SHANGHAI – Newly minted Zai Lab Ltd., of Shanghai, has made its eagerly awaited debut announcement, obtaining global rights to two Sanofi SA preclinical compounds for chronic respiratory diseases.
A year after its official launch, Curtana Pharmaceuticals Inc. stepped onstage holding a $7.6 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund its lead cancer therapy program, which is targeting the OLIG2 transcription factor (TF) – initially in glioblastoma multiforme (GBM).
More Newco News Headlines

Cast Your Vote

Has biotech’s bubble burst?: